A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

NCT05382325 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors

Interventions

BIOLOGICAL: MK-1484
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC